Evaluation of Safety and Efficacy of Mersina, An Ayurvedic formulation: A double blind, placebo controlled study in type 2 diabetic patients with Secondary failure to Oral drugs

Evaluation of Safety and Efficacy of Mersina, an Ayurvedic formulation: A double blind, placebo controlled study in type 2 diabetic patients with Secondary failure to Oral drugs - Mersina - Herbal Ayurvedic FOrmulation

Status

Active, not recruiting

Phases

Phase 2

Study type

Observational

Source

CTRI

Registry ID

CTRI/2009/091/000560

Enrollment

Registered

2009-09-03

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Mersina (Antidiabetic Ayurvedic formulation): 3 g/day, 3 months Control Intervention1: CORN STARCH: 3g /day, 3 months

Eligibility

Inclusion criteria

Inclusion criteria: Secondary failure to Oral Hypoglycemic Agents was diagnosed if the patient had HbA1c levels > 8.5% even after supplementation of maximal dose of a combination of a sulphonylurea (15 mg glybenclamide or 160 mg gliclazide or 15 mg glipizide) and metformin 1500 mg/day.

Exclusion criteria

Exclusion criteria: Patients with ketosis, diabetes related complications, hepatic or renal disease, pancreatitis, cardiac problems, uncontrolled hypertension, malnutrition and severe immune deficiency.

Design outcomes

Primary

Measure	Time frame
Antidiabetic activityTimepoint: 3 months	—

Secondary

Measure	Time frame
Improvement in metabolic, insulin level, HbA1c level, kidney and lipid profileTimepoint: 3 months	—

Countries

India

Contacts

Public ContactDr Sateesh Belemkar

satishb9@gmail.com02563286545

Outcome results